ATE391177T1 - Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab - Google Patents

Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab

Info

Publication number
ATE391177T1
ATE391177T1 AT98908593T AT98908593T ATE391177T1 AT E391177 T1 ATE391177 T1 AT E391177T1 AT 98908593 T AT98908593 T AT 98908593T AT 98908593 T AT98908593 T AT 98908593T AT E391177 T1 ATE391177 T1 AT E391177T1
Authority
AT
Austria
Prior art keywords
compositions
modulating
kappa
methods
kappab
Prior art date
Application number
AT98908593T
Other languages
English (en)
Inventor
Anthony Manning
Frank Mercurio
Irit Alkalay
Yinon Ben-Neriah
Aaron Ciechanover
Avraham Yaron
Original Assignee
Signal Pharm Llc
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc, Yissum Res Dev Co filed Critical Signal Pharm Llc
Application granted granted Critical
Publication of ATE391177T1 publication Critical patent/ATE391177T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98908593T 1997-02-18 1998-02-18 Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab ATE391177T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/802,322 US5932425A (en) 1997-02-18 1997-02-18 Compositions and methods for modulating cellular NF-κB activation

Publications (1)

Publication Number Publication Date
ATE391177T1 true ATE391177T1 (de) 2008-04-15

Family

ID=25183386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908593T ATE391177T1 (de) 1997-02-18 1998-02-18 Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab

Country Status (9)

Country Link
US (1) US5932425A (de)
EP (1) EP1009824B1 (de)
JP (2) JP4560616B2 (de)
AT (1) ATE391177T1 (de)
AU (1) AU6659198A (de)
CA (1) CA2281920C (de)
DE (1) DE69839326T2 (de)
HK (1) HK1028784A1 (de)
WO (1) WO1998036070A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0920518A1 (de) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Von einem stimulus induzierbarer i(kappa)b kinase komplex
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1998029101A1 (en) 1996-12-31 1998-07-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999066065A2 (en) * 1998-06-13 1999-12-23 Zarpex Biosciences Limited Proteasomal activity
ES2361660T3 (es) * 1998-12-10 2011-06-21 Signal Pharmaceuticals Llc Ubicutina-ligasa e3 humana para la modulación de nk-kappa b.
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
WO2001010384A2 (en) 1999-08-10 2001-02-15 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2801902B1 (fr) * 1999-12-01 2005-03-04 Centre Nat Rech Scient Procedes de criblages fonctionnels d'agents aptes a moduler l'activite des complexes ubiquitine-ligases scf et leurs applications
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030044852A1 (en) * 2000-08-10 2003-03-06 Joslin Diabetes Center, Inc., A Massachusetts Corporation Methods for treatment of insulin resistance
US20060287337A1 (en) * 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
AU2002349784A1 (en) * 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
FR2859733A1 (fr) * 2003-09-15 2005-03-18 Centre Nat Rech Scient Procede de criblage fonctionnel d'agents aptes a moduler l'activite des ubiquitine hydrolases et leurs applications
CN1926395B (zh) * 2004-03-02 2010-10-13 宝洁公司 用于固化高内相乳液的方法
FR2867783B1 (fr) * 2004-03-16 2008-02-01 Cytomics Systems Procede de criblage d'agent modulant l'ubiquitination de la proteine ikbalpha et moyens destines a la mise en oeuvre dudit procede
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
US20100292306A1 (en) * 2005-05-24 2010-11-18 Carlson C George Compositions And Methods For The Treatment Of Muscular Dystrophy
WO2007101202A1 (en) * 2006-02-27 2007-09-07 Research Development Foundation Cell-targeted ikb and methods for the use thereof
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2010044892A1 (en) * 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
CN113423435A (zh) 2018-12-28 2021-09-21 雷杰纳荣制药公司 使用花生四烯酸15-脂氧合酶(alox15)抑制剂治疗呼吸系统病症

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122463A (en) * 1990-05-17 1992-06-16 Massachusetts Institute Of Technology Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor
EP0669976B1 (de) * 1992-10-29 1999-06-16 Medical Research Council Testreihenanalyse-Verfahren mit transkriptionsfaktor DP-1
DE4243770A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
WO1997000690A1 (en) * 1995-06-23 1997-01-09 Tularik, Inc. Interleukin-1 receptor-associated protein kinase and assays
EP0920518A1 (de) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Von einem stimulus induzierbarer i(kappa)b kinase komplex

Also Published As

Publication number Publication date
DE69839326D1 (de) 2008-05-15
WO1998036070A1 (en) 1998-08-20
DE69839326T2 (de) 2009-04-16
EP1009824A1 (de) 2000-06-21
JP2001512319A (ja) 2001-08-21
AU6659198A (en) 1998-09-08
EP1009824B1 (de) 2008-04-02
CA2281920C (en) 2010-05-04
US5932425A (en) 1999-08-03
JP2010063461A (ja) 2010-03-25
HK1028784A1 (en) 2001-03-02
CA2281920A1 (en) 1998-08-20
JP4560616B2 (ja) 2010-10-13

Similar Documents

Publication Publication Date Title
DE69839326D1 (de) ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69711067D1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
ATE413386T1 (de) Ppar-gamma modulatoren
EA199800667A1 (ru) Новые фенантридины
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
ES2179355T3 (es) Derivados de tiazol utilizados como inhibidores de proteina quinasa c.
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
WO2000053774A3 (en) Metalloproteinases and methods of use therefor
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
PT1105728E (pt) Modulacao de proteinas
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ES2186807T3 (es) Inhibidores de trombina.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
DE69738600D1 (de) Neuroaktive peptide
ATE433495T1 (de) Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE68920525D1 (de) Verfahren zur Definierung der Anwendung von Fernsprechertasten.
DE69738945D1 (de) Rken
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
ATE160698T1 (de) Angiogenin und/oder alpha1-microglobulin und/oder komplementfaktor d zur begrenzung der sekretion von proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties